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SUMMARY: Ecstasy is one of the most popular amusing drugs among young people. Documents indicate some effects of
Ecstasy on hippocampus and close relations between dopaminergic functions with reward learning. Therefore, the aim of this study was
evaluation of the chronic effects of Ecstasy on memory in male Wistar rats and determination of dopamine receptors' gene expression in
hippocampus. Forty adult male Wistar rats randomly distributed in five groups: Control, sham (received 1 ml/kg 0.9% saline) and three
experimental groups were: Exp. 1 (2.5 mg/kg), Exp. 2 (5 mg/kg), and Exp. 3 (10 mg/kg) received MDMA intraperitoneally once every
7 days (3 times a day, 3 hours apart) for 4 weeks. Before the first injection animals trained in Shuttle Box memory and tested after the last
injection.  24 hours after the final testing, brains of rats were dissected and hippocampus was removed and homogenized. After total
RNA extraction and cDNA synthesis, expression of dopamine receptor genes in the hippocampus determined with Real-Time PCR. Our
results showed that 2.5 and 5 mg/kg MDMA-treated groups had memory impairment. Also we found that MDMA increased the mRNA
expression of dopamine receptors in hippocampus and the highest increase found in dopamine D1 receptors in the 5 mg/kg experimental
group. We concluded that low doses of Ecstasy could increase Dopamine takers gene expression in hippocampus and disorder avoidance
memory. But in high doses the increase in Dopamine takers gene expression was not as much as that in low doses and avoidance memory
disorder was not observed.
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INTRODUCTION
Today MDMA (3,4-methylenedioxy-
metamphetamine) is one of the most popular drugs among
the young, especially at dance parties because of its ability
to induce attraction and increasing energy (Cohen 1995;
Kindlundh-Högberg et al., 2006). Ecstasy (MDMA) acts as
a stimulant and mescaline-like hallucinogen, and is known
to suppress the appetite (Cohen; Green et al., 2003).
Frequent and prolonged use of MDMA causes
depression, anxiety and aggression, but it has also been
accompanied with cognitive changes, loss of shyness,
impulsivity, memory loss, and eating disorders in human
and rats (Cohen; Morgan, 1998; McCann et al., 1999; Morley
et al., 2001; Curran et al., 2004; McCardle et al., 2004;
Gouzoulis-Mayfrank et al., 2005; Kindlundh-Högberg et al.).
Some documents indicate a close relations in
hippocampus between dopaminergic functions of reward
related-associative learning (Di Chiara, 1999), reward
prediction and incentive salience (Berridge & Robinson,
1998; Schultz 1998; Everitt et al., 1999), and serotonergic
functions of disinhibition and impulsivity (Linnoila et al.,
1983; Af Klinteberg et al., 1990; Winstanley et al., 2004)
because of numerous specific interactions between the two
systems.
The issue whether compulsive MDMA-taking
behavior mostly is regulated by dopamine or serotonin
related functions is very important to understand the
implication and role of MDMA in mechanisms of addictive
behaviors (Kindlundh-Högberg et al.).
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There are several limitations in accompanying
researches on MDMA-taking; for example, ecstasy is
administered in dose regimes that poorly imitate the
behaviors observed among young person's taking this drug
on a weekly or at least intermittent basis at dance clubs.
Instead MDMA, in most previous studies, was either
administered as a single dose or multiple doses for 17 days
(Gold & Koob, 1989; Taylor & Jentsch, 2001; Fone et al.,
2002; McGregor et al., 2003). Secondly, studies of MDMA
caused long-term effects have focused on mechanisms that
occur some days after drug discontinuation reflecting
peripheral or withdrawal effects rather than effects of
repeated long-term intake (Green et al.). Third, several
studies have reported effects upon behavior (locomotion,
conditioned place preference, self-administration), protein
density (autoradiography), neurotransmitters and their
metabolites (micro dialysis) (Green et al.; Piper & Meyer,
2004), but it still remains unclear whether observed
alterations also involve changes in mRNA contents of
included markers. Finally, many studies have focused on
single or a few markers in single brain structures, and there
is no comprehensive testing of dopaminergic and
serotonergic markers simultaneously in multiple brain
regions (Kindlundh-Högberg et al.).
We hypothesize that alterations of gene transcript
levels of markers implicated in mechanisms regulating
rewarding properties underlie the psychiatric changes that
have been reported to be associated with MDMA intake.
The specific aim of the present study was to investigate how
the repeated intermittent administration of MDMA affects
the gene-transcript content of dopamine receptors in regions
of the male rat hippocampus implicated in memory loss.
MATERIAL AND METHOD
Animals. Eight week male Wistar rats (Pasteur Institute,
Tehran, Iran) weight 200±20 g at the initiation of the study,
served as subjects and were housed pair-wise in air
conditioned rooms (12:12-h dark/light cycle) at 22±3 °C and
a humidity of 53%. The rats were randomly distributed into
three MDMA-treated (-3,4-methylenedioxy-N-
methamphetamine-HCl), Sigma Pharmaceutical) and Sham
groups. All animals received three intraperitoneal injections
(3 h apart; a challenge) every 7 day for 4 weeks. The MDMA
was dissolved into the vehicle on the day of testing. During
the treatment day the MDMA low-dose (n=8) received 3
2.5 mg/kg MDMA, the MDMA middle dose (n=8) 3 x 5
mg/kg, the MDMA high dose rats (n=8) 3 x 10 mg/kg
whereas Sham group received the vehicle of sterile 0.9%
saline solution (1 ml/kg). The rationale for these doses of
MDMA stems from human conditions. MDMA is taken at
doses of 50-60 mg in humans. One single dose of 5 mg/kg
per rat corresponds to 65 mg in a 65 kg human according to
the interspecies scaling technique: D human = D animal (W
human/W animal) 0.7 (Mordenti et al., 1991). The Golestan
University of Medical sciences Guidelines for the Care and
Use of Animals in Research were followed.
Inhibitory Avoidance Apparatus. The step-through
inhibitory avoidance apparatus consisted of two
compartments of the same size (20 x 20 x 30 cm3). In the
middle of a dividing wall, a guillotine door (7.9 cm2) could
be lifted manually. The walls and floor of one compartment
consisted of white opaque resin and the walls of the other
compartment were dark. Stainless steel bars (3 mm in
diameter and 1 cm intervals) constituted the floor of the dark
compartment. Intermittent electric shocks (50 Hz, 3 s, 1.5
mA intensity) were delivered to the grid floor of the dark
compartment by an isolated stimulator.
Behavioral Procedures. Our previous study (Azami et al.,
2010) described passive avoidance as follows: All animals
were allowed to habituate in the experimental room (with
light and sound attenuated) for at least 30 min prior to the
experiments. Then, each animal was gently placed in the
brightly lit compartment of the apparatus; after 5 s the
guillotine door was opened and the animal was allowed to
enter the dark module.
The latency with which the animal entered the dark
chamber was recorded. Animals that waited more than 120
s to enter the dark chamber were excluded from the
experiments.
Once the animal entered with all four-paws to the
next chamber, the guillotine door was closed and the rat was
immediately withdrawn from the compartment. This trial
was repeated after 30 min. As in the acquisition trial, after 5
s the guillotine door was opened, and as soon as the animal
entered the dark (shock) compartment the door was closed;
and a foot shock (50 Hz, 1 mA and 3 s) was immediately
delivered to the grid floor of the dark room. After 20 s, the
rat was removed from the apparatus and placed temporarily
into its home cage. Two minutes later, the animal was retested
in the same way as in the previous trials; if the rat did not
enter the dark compartment during 120 s, a successful
acquisition of inhibitory avoidance response was recorded.
Otherwise, when the rat entered the dark compartment
(before 120 s) a second time, the door was closed and the
animal received the shock again. After retesting, if the rat
learned inhibitory avoidance response successfully, it was
moved to the cage. On the test day each animal was gently
placed in the light compartment and after 5 s the door was
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opened, and step through latency (sec) was recorded in the
absence of electric foot shocks, as indicator of inhibitory
avoidance behavior.
Thirty minutes after the last injection of MDMA the
rats tested in Shuttle box and 24 h after the final test, the
brains of rats were dissected.Brain region of interest
hippocampus (at bregma 4.8 to 5.6), were dissected using a
rat brain matrix (Paxinos & Watson, 2007), rapidly frozen
on dry ice, immersed in RNA later (Ambion) for 1 h, and
then stored at -80 °C. All procedures were performed in
accordance with institutional guidelines for animal care and
use.
Isolation of total RNA and reverse transcriptase. After
homogenizing of the hippocampus tissue, total RNA were
isolated with RNeasy Mini Kits (Qiagen, Germany),
following the manufacturers protocol and recovered in 20
µL elution solution. Then, reverse transcription was done
with equal amounts of RNA using Omniscript kit Qiagen,
Germany) to generate cDNA template for real-time
polymerase chain reaction (PCR) according to the
manufacturer’s protocol. The cDNA templates were
evaluated by PCR and gel-electrophoresis.
Quantitative Real-Time PCR. Quantitative real-time PCR
(Q RT-PCR) was used blindly on the samples (ABI 7300;
USA) using the Power SYBR Green PCR Master Mix
(Applied Biosystems) to analyze the transcript levels of
dopamine receptors in total volume 25 µl.
Amplification was done for 40 cycles at four stages:
Stage 1: 50 °C for 2 minutes; Stage 2: 95 °C for 1 minute;
Stage 3: 95 °C for 15 seconds and 62 °C for 1.5 minutes;
Stage 4: 95 °C for 15 seconds, 60 °C for 30 seconds and 95
°C for 15 seconds.
Primers used for Q RT-PCR. Primers pairs of the internal
housekeeping gene (s18 RNA) and the dopamine receptors
were designed to Primers-3 software and National Center
for Biotechnology Information (NCBI):
Primers of s18 RNA; gtgatccccgagaagtttca;
ctgctttcctcaacaccaca
Dopamine D1 receptor primer; tccttcaagagggagacgaa;
ccacacaaacacatcgaagg
Dopamine D4 receptor primer; gatgtgttggacgcctttct;
tcggcattgaagatggtgta
Dopamine D5 receptor primer; ccacatgataccgaatgcag;
cacagtcaagctcccagaca
Statistical analysis. Statistical analyses for memory
experiment were performed using one-way ANOVA. Gene
expression fold was calculated relative to the level of each
sample of the housekeeping gene, S18 RNA using Microsoft
Excel® 2-∆∆ct = PRODUCT(2^-((A4-B4)-(C4-D4))) . The
differences with P< .05 were considered statistically
significant.
RESULTS
As we show in Figure 1, the present study showed
that the Saline group got amnesia due to the lapse of time
with the average of 27.5 s delay in entering the black house/
cell. But it seemed that the Ecstasy effected the recalling of
the memory in experimental group and because of the amount
of dose rats got less amnesia. In other words most of rats
Fig. 1. Delay time (per second) to entrance to dark chamber after one month.
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with complete memory/recall were observed
in 10 mg/kg dose (Fig. 1).
The expression profiles of these three
genes relative to s18 RNA showed that the
injection of MDMA increase the D1, D4, and
D5 Dopamine receptors gene expression in
comparison with control and control-Saline
groups.
Considering this point is essential that
diagram of this gene expression changes is
sinuous and its peak is in T2 (5 mg/kg
MDMA). In other words the most increase of
gene expression was observed for all three
Dopamine takers in this group.
D1, D4 and D5 receptors gene
expression in 2.5 mg/kg group were increased
in comparison with Sham. The highest
expression of the receptor revealed in D1 re-
ceptor (Figs. 2–4).
D1, D4 and D5 receptors gene expression
in 5 mg/kg group had a higher level in
comparison with Sham. Also the highest
expression of the receptors revealed in D1 re-
ceptor while D4 receptor gene expression in this
group is not much difference in comparison with
low dose group (Fig. 2–4).
D1, D4 and D5 receptors gene expression in 10
mg/kg group were increased. Also the highest
expression of the receptors revealed in D4 re-
ceptor and also D4 receptor gene expression in
this group is not much difference in comparison
with 2.5 and 5 mg/kg dose group (Figs. 2–4).
DISCUSSION
There are several behavioral patterns to
test memory and learning in laboratory animals.
But during recent years passive avoidance
memory as a learning model has been used
extensively (Azami et al.). The present study
showed that taking 2.5 and 5 mg/kg doses of
MDMA over long periods (4 weeks) destroyed
memory on one hand, and increased the gene
expression Dopamine receptors, although taking
10 mg/kg of MDMA over long periods (4 weeks)
had no destructive effects on memory in spite
Fig. 2. D1 Dopamine receptor genes expression in all groups. C= Control, SH=
Sham, T1= 2.5 mg/kg, T2= 5 mg/kg and T3= 10 mg/kg MDMA.
Fig. 3. D4 Dopamine receptor genes expression in all groups. C= Control, SH=
Sham, T1= 2.5 mg/kg, T2= 5 mg/kg and T3= 10 mg/kg MDMA.
Fig. 4. D5 Dopamine receptor genes expression in all groups. C= Control, SH=
Sham, T1= 2.5 mg/kg, T2= 5 mg/kg and T3= 10 mg/kg MDMA.
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of decreasing in the gene expression Dopamine receptors,
comparing to other experimental groups; although, it was
more than the performance of gene expression Dopamine
receptors group which showed that beside the instruction of
animals, taking MDMA was effective on memory and the
level of gene expression.
Another considerable point was our given
Dopamine receptors different reactions to MDMA.
Dopamine receptors were divided into two groups of D1-
like (D1, D5) and D2-like (D2, D3, D4) (Brennan et al.,
2009). In this study we observed that the Maximum level
of gene expression Dopamine receptors of D2-like (D2,
D3, D4) meant D4 sustained little change by the increase
of MDMA dose. But the level of gene expression
Dopamine takers of D1-like (D1, D5) had considerable
changes by the alternation of MDMA dose. Therefore,
probably, the takers expression of D1-like (D1, D5) was
largely related to the dose of drug while the maximum of
the takers expression of D2-like (D2, D3, D4) was in
specific dose and with the increase of drug not so much
changes did not observed. Behavioral disorders were
reported among people who took Amphetamine for 3
months (Richards et al., 1993).
Amphetamine caused permanent behavioral disorders
Morris Maze Water (MMW) among animals that took
(Friedman et al., 1998), Also METH and
parachloroamphetamine (PCA) caused drawback in passive
avoidance (PA) learning and considerable decrease in their
Dopamine, Serotonin, and their metabolisms in different
regions of brain. In contrast, taking MDMA decreased
Dopamine in anterior striatum and cingulated and did not
disorder avoidance memory (Murnane et al., 2012).
MDMA, METH and PCA have different abilities
in avoidance memory due to their different neuro-chemical
effects. In this regard METH and PCA destruct avoidance
memory while MDMA neither caused the secretion of
neurotransmitters nor avoidance memory disorders
(Murnane et al.). The researchers also showed in the present
that higher doses of MDMA did not destruct avoidance
memory, but they did not find similar cases regarding the
Dopamine receptors gene expression. Previous studies
showed that avoidance memory did not dependent on
Serotonin (Santucci et al., 1996; Barrionuevo et al., 2000;
Myhrer, 2003). Moreover, Serotonin did not decrease by
METH and PCA. The present report confirmed the
previous studies which showed that avoidance memory
was mediated by Dopaminergic system (Sugimoto et al.,
2001). On the other hand, processes related to Dopamine
which were related to memory and learning might be
disordered because of Amphetamine (Murnane et al.).
The results of this study also confirmed that
Amphetamine derivatives could disorder the avoidance
memory. Although no memory disorder was observed in high
MDMA dose (10 mg/kg).
Those who take sustain prolonged habits (Williamson
et al., 1997). It is essential to consider this point that although
memory and learning disorders exist among MDMA takers
(Kalechstein et al., 2007), but the results of the present study
did not completely match with the previous studies; this
might be due to the memory and learning complicated
process and the point that each Amphetamine compounds
causes special disorder (Murnane et al., 2012).
Regarding to this point it is hard to generalize the
results of an animal study to one of people addicted to
Amphetamine. On the other hand, avoidance memory can
show memory disorders but it can be used just as a preclinical
investigation (Kalechstein et al.). Therefore, comparing the
results of this study to the reports about addiction can be useful
in finding a way to treat the disorders (Murnane et al.).
It was shown in previous studies that MDMA takers
had neurotic disorders in Hippocampus. Its long term intake
affected Serotonin and lead to hippocampus memory
disorders (Gudelsky & Yamamoto, 2008). Moreover
Serotonergic neurons in median raphe which are targeted
by hippocampus neurons activates 5HT1A-rec in neurogenesis
in dentate gyrus (Azami et al., 2009).
Recently in post mortem studies it has been reported
that individuals with long term Met Amphetamine (METH)
background sustained low level of Dopamine, Tyrosine,
Hydroxylase, and Dopamine vectors (Wilson et al., 1996).
In similar research in vivo the decrease in the amount of
Dopamine vectors among METH takers were reported
(McCann et al., 1998). But considering the possibility of
operational differences in various Amphetamines in the
present study, the researchers showed that MDMA increased
Amphetamine receptors which were related to dose, taking
high doses of Amphetamine compounds of Dopaminergic
and Serotonergic systems in lab animals' brain (Bittner et
al., 1981). Investigations have showed that prolonged
Amphetamine (6-8 months) decreased Dopamine and
Serotonin levels in brain tissue (Sanders-Bush et al., 1975;
Friedman et al.; Cass & Manning, 1999).
In several previous studies it has been shown  that PVA
specifically provokes Serotonin secretion (Steranka et al.,
1977; Steranka & Sanders-Bush, 1980; Adriani et al., 1998),
meanwhile some other studies showed that PCA effects were
mediated by Dopaminergic activities (O'Callaghan & Miller,
1994; Itzhak et al., 2004). Moreover, PCA dose influenced
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the amount of Dopamine and Serotonin secretion (Stone et
al., 1987). Studies on the effects of MDMA and METH on
small mice showed the influence of Dopaminergic (Hirata et
al., 1995; Renoir et al., 2008) and Serotonergic (Scatton et
al., 1980; Shankaran & Gudelsky, 1998) systems.
It is not clear yet why such discrepancies are observed
but it seems the obtained results are affected by laboratory
conditions such as drug dose, amount of training to animals,
race differences and etc. (Murnane et al.).
PCA had high capacity to secrete Serotonin while
both MDMA and METH decreased Serotonin level in six
regions of brain (hippocampus, hypothalamus, PFC, NACs,
striatum, brain stem) (Murnane et al.).
These three compounds cause secretion of Dopamine
in post striatum but METH and PCA specifically decrease
Dopamine level in ant striatum. Although these three
compounds decrease Dopamine metabolite; Dopamine in
post striatum, but only METH and PCA specifically cause
the secretion of DOPAC in ant striatum and increase of
hydroxyl-vanillic acid (HVA) in post striatum. In the same
way only METH and PCA increase the textual level of
metabolic Serotonin, 5-HLAA in frontal cortex and cingulate
(Murnane et al.).
Although Hippocampus plays a main role in memory
and learning process, but doesn't change in Serotonin
receptors gene expression as a consequence of MDMA taking
in this region of the brain. But in hypothalamus the increase
in 5HT2C and 5HT3 receptors gene expression is observed
and in this region some changes in Dopamine receptors gene
expression by increasing expression in D3-rec (in high and
low dose of MDMA taking). Actually, Dopamine receptors
gene expression in limbic system and nigrostriatum are not
influenced by MDMA (Kindlundh-Högberg et al.).
Hippocampus is innervated by Dopamine neurons
(Scatton et al.) and addiction to MDMA is also the result of
progressive increase in Dopamine in hippocampus
(Shankaran & Gudelsky), but this increase does not happen
in striatum. It was also shown that nervous noradrenergic
terminals were the sources of increase in outer cell surface
of Dopamine in Hippocampus on the influence MDMA
which this mechanism itself was influenced by the increase
of amine tyrosine acid in brain (Shankaran & Gudelsky).
MDMA in mature mice increased proliferation in
dentate gyrus and, of course, decrease progenitor cells. But
those results did not show the same effects in animal took
low dose (1.25 mg/kg) and medium dose (2.5 mg/kg)
(Catlow et al., 2010).
In vitro studies demonstrated that the addiction to
MDMA differentiated neuron cells from neural stem cells
in granular layer in dentate gyrus (Azami et al., 2009); while
other studies showed that MDMA could cause neurogenesis
(Catlow et al.).
CONCLUSION
This study revealed that low doses of Ecstasy could
increase Dopamine takers gene expression in hippocampus
and disorder avoidance memory. But in high doses the
increase in Dopamine takers gene expression was not as
much as that in low doses and avoidance memory disorder
was not observed.
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SIMIN, M.; MEHRDAD, J.; KAMRAN, H. & MAJID, S. La
expresión génica de receptores de dopamina en el hipocampo de
ratas macho después de la administración de MDMA (éxtasis). Int.
J. Morphol., 33(1):301-308, 2015.
RESUMEN: El éxtasis es una de las drogas de diversión
más populares entre los jóvenes. La investigación reporta algu-
nos de los efectos del éxtasis sobre el hipocampo y la relación
entre las funciones dopaminérgicas con la recompensa en el apren-
dizaje.  El objetivo de este estudio fue la evaluación de los efec-
tos crónicos del éxtasis en la memoria de ratas macho Wistar y la
determinación de la expresión de genes receptores de dopamina
en el hipocampo. Cuarenta ratas macho adultas fueron distribui-
das al azar en cinco grupos: grupo control, simulado (a 1 ml/kg
0,9% de solución salina) y tres grupos experimentales: Grupo
exp. 1 (2,5 mg/kg), Exp. 2 (5 mg/kg), y Exp. 3 (10 mg/kg) reci-
bió MDMA vía intraperitoneal cada 7 días (3 veces al día, con 3
horas de diferencia) durante 4 semanas. Antes de la primera in-
yección los animales fueron entrenados en memoria Shuttle Box
y examinados después de la última inyección. Veinticuatro horas
después de la prueba final, los cerebros de las ratas fueron
diseccionados, el hipocampo fue separado y homogeneizado.
Después de la extracción total de ARN y síntesis de ADNc, la
expresión de genes de los receptores de dopamina en el
hipocampo fue determinado con PCR en tiempo real. Nuestros
resultados mostraron que los grupos de 2,5 kg y 5 mg/MDMA
tratados tenían deterioro de la memoria. Además, encontramos
que la MDMA aumentó la expresión de ARNm de los receptores
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de dopamina en el hipocampo y el aumento mayor se observó
en los receptores D1 de dopamina en el 5 mg/kg Grupo experi-
mental. En conclusión, las dosis bajas de éxtasis podrían aumen-
tar tomadores de expresión génica de la dopamina en el
hipocampo y trastornos de la memoria. Sin embargo, en dosis
altas el aumento de la expresión génica no mostró un aumento
significativo, a diferencia de los resultados con dosis bajas,  tam-
poco  se observaron trastornos disociativos de memoria.
PALABRAS CLAVE: MDMA; Receptores de
dopamina; Expresión génica; Hipocampo; Rata.
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